Syntara Employee Directory
Biotechnology ResearchNew South Wales, Australia51-200 Employees
Syntara Limited is a clinical-stage biotechnology company focused on therapies for extracellular matrix dysfunction. Based in Frenchs Forest, New South Wales, it applies amine oxidase chemistry and related technologies to develop medicines for blood cancers and diseases driven by inflammation and fibrosis. Listed on the Australian Securities Exchange as SNT, the company is advancing several phase 2 trials and evaluating additional early-stage programs for 2024. Its lead candidate, SNT-5505, is being developed for myelofibrosis and has FDA Orphan Drug Designation and IND clearance, with a phase 2 program including a combination study with a JAK inhibitor and interim data anticipated in 2024. In addition to SNT-5505, Syntara pursues collaborations and programs such as pan-LOX inhibitors for scar prevention with the University of Western Australia and SNT-4728 in partnership with Parkinson’s UK to target sleep disorders and neuroinflammation.